Lipid-related genes and myocardial infarction in 4685 cases and 3460 controls: Discrepancies between genotype, blood lipid concentrations, and coronary disease risk

International Journal of Epidemiology

Volumn 33, Issue 5, 2004, Pages 1002-1013

  Keavney, Bernard ^a   Palmer, Alison ^b   Parish, Sarah ^b   Clark, Sarah ^b   Youngman, Linda ^b   Danesh, John ^c   McKenzie, Colin ^d   Delépine, Marc ^e   Lathrop, Mark ^e   Peto, Richard ^b   Collins, Rory ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF THE WEST INDIES   (Jamaica)

^e CENTRE NATIONAL DE GÉNOTYPAGE   (France)

Author keywords

Coronary heart disease; Genetics; Lipids

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; CHOLESTEROL ESTER TRANSFER PROTEIN;

BLOOD; CARDIOVASCULAR DISEASE; GENETICS; POLYMORPHISM; RISK ASSESSMENT;

ADULT; ALLELE; ARTICLE; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HEART INFARCTION; HEREDITY; HUMAN; HYPERTENSION; LINEAR REGRESSION ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING HABIT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; APOLIPOPROTEIN A-I; APOLIPOPROTEINS; APOLIPOPROTEINS B; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GREAT BRITAIN; HUMANS; LIPIDS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 7244250124     PISSN: 03005771     EISSN: None     Source Type: Journal    
DOI: 10.1093/ije/dyh275     Document Type: Article

References (60)

1. Zondervan KT, Cardon LR. The complex interplay among factors that influence allelic association. Nat Rev Genet 2004;5 89-100.
2. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026-33.
3. Ahn YI, Kamboh MI, Hamman RF, Cole SA, Ferrell RE. Two DNA polymorphisms in the lipoprotein lipase gene and their associations with factors related to cardiovascular disease. J Lipid Res 1993; 34 421-28.
4. Anderson JL, King GJ, Bair TL et al. Association of lipoprotein lipase gene polymorphisms with coronary artery disease. J Am Coll Cardiol 1999;33:1013-20.
5. Boer JM, Ehnholm C, Menzel HJ et al. interactions between lifestyle-related factors and the ApoE polymorphism on plasma lipids and apolipoproteins. The EARS Study. European Atherosclerosis Research Study. Arterioscler Thromb Vasc Biol 1997;17 1675-81.
6. Brazier L, Tiret L, Luc G et al. Sequence polymorphisms in the apolipoprotein(a) gene and their association with lipoprotein(a) levels and myocardial infarction. The ECTIM Study. Atherosclerosis 1999;144:323-33.
7. Corbo RM, Vilardo T, Ruggeri M, Gemma AT, Scacchi R. Apolipoprotein E genotype and plasma levels in coronary artery disease. A case-control study in the Italian population. Clin Biochem 1999; 32:217-22.
8. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988;8:1-21.
9. Hannuksela ML, Liinamaa MJ, Kesaniemi YA, Savolainen MJ. Relation of polymorphisms in the cholesteryl ester transfer protein gene to transfer protein activity and plasma lipoprotein levels in alcohol drinkers. Atherosclerosis 1994;110:35-44.
10. Hokanson JE. Lipoprotein lipase gene variants and risk of coronary disease: a quantitative analysis of population-based studies. Int J Clin Lab Res 1997;27:24-34.
11. Jemaa R, Fumeron F, Poirier O et al. Lipoprotein lipase gene polymorphisms: associations with myocardial infarction and lipoprotein levels, the ECTIM study. Etude Cas Temoin sur l'Infarctus du Myocarde. J Lipid Res 1995;36:2141-46.
12. Moreel JF, Roizes G, Evans AE et al. The polymorphism ApoB/4311 in patients with myocardial infarction and controls: the ECTIM Study. Hum Genet 1992;89:169-75.
13. Regis-Bailly A, Visvikis S, Steinmetz J et al. Frequencies of five genetic polymorphisms in coronarographed patients and effects on lipid levels in a supposedly healthy population. Clin Genet 1996;50:339-47.
14. Reymer PW, Gagne E, Groenemeyer BE et al. A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis. Nat Genet 1995; 10:28-34.
15. Tybjaerg-Hansen A, Steffensen R, Meinertz H, Schnohr P, Nordestgaard BG. Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N Engl J Med 1998;338:1577-84.
16. Wittrup HH, Tybjaerg-Hansen A, Abildgaard S, Steffensen R, Schnohr P, Nordestgaard BG. A common substitution (Asn291Ser) in lipoprotein lipase is associated with increased risk of ischemic heart disease. J Clin Invest 1997;99:1606-13.
17. Wittrup HH, Tybjaerg-Hansen A, Steffensen R et al. Mutations in the lipoprotein lipase gene associated with ischemic heart disease in men. The Copenhagen city heart study. Arterioscler Thromb Vasc Biol 1999;19:1535-40.
18. Keavney B, McKenzie C, Parish S et al. Large-scale test of hypothesised associations between the angiotensin-converting enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. Lancet 2000;355:434-42.
19. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-70.
20. Parish S, Collins R, Peto R et al. Cigarette smoking, tar yields, and non-fatal myocardial infarction: 14 000 cases and 32 000 controls in the United Kingdom. The International Studies of Infarct Survival (ISIS) Collaborators. BMJ 1995;311:471-77.
21. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 1999;20:725-41.
22. Peacock RE, Hamsten A, Nilsson-Ehle P, Humphries SE. Associations between lipoprotein lipase gene polymorphisms and plasma correlations of lipids, lipoproteins and lipase activities in young myocardial infarction survivors and age-matched healthy individuals from Sweden. Atherosclerosis 1992;97:171-85.
23. Navajas M, Laurent AM, Moreel JF et al. Detection by denaturing gradient gel electrophoresis of a new polymorphism in the apolipoprotein B gene. Hum Genet 1990;86:91-93.
24. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-48.
25. Kuivenhoven JA, de Knijff P, Boer JMA et al. Heterogeneity at the CETP gene locus - influence on plasma CETP concentrations and HDL cholesterol levels. Arterioscler Thromb Vasc Biol 1997;17:560-68.
26. Clark S, Youngman LD, Palmer A, Parish S, Peto R, Collins R. Stability of plasma analytes after delayed separation of whole blood: implications for epidemiological studies. Int J Epidemiol 2003; 32:125-30.
27. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-74.
28. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.
29. Plummer M. Improved estimates of floating absolute risk. Stat Med 2004;23:93-104.
30. Freeman DJ, Griffin BA, Holmes AP et al. Regulation of plasma HDL cholesterol and subfraction distribution by genetic and environmental factors. Associations between the TaqI B RFLP in the CETP gene and smoking and obesity. Arterioscler Thromb 1994;14 336-44.
31. Fumeron F, Betoulle D, Luc G et al. Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction. J Clin invest 1995;96:1664-71.
32. Heiba IM, DeMeester CA, Xia YR et al. Genetic contributions to quantitative lipoprotein traits associated with coronary artery disease: analysis of a large pedigree from the Bogalusa Heart Study. Am J Med Genet 1993;47:875-83.
33. Kondo I, Berg K, Drayna D, Lawn R. DNA polymorphism at the locus for human cholesteryl ester transfer protein (CETP) is associated with high density lipoprotein cholesterol and apolipoprotein levels. Clin Genet 1989;35:49-56.
34. Kuivenhoven JA, Jukema JW, Zwinderman AH et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998;338:86-93.
35. Ordovas JM, Cupples LA, Corella D et al. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler Thromb Vasc Biol 2000;20:1323-29.
36. Tenkanen H, Koshinen P. Kontula K et al. Polymorphisms of the gene encoding cholesterol ester transfer protein and serum lipoprotein levels in subjects with and without coronary heart disease. Hum Genet 1991;87:574-78.
37. Ukkola O, Savolainen MJ, Salmela PI, von Dickhoff K, Kesaniemi YA. DNA polymorphisms at the locus for human cholesteryl ester transfer protein (CETP) are associated with macro- and microangiopathy in non-insulin-dependent diabetes mellitus. Clin Genet 1994;46 217-27.
38. Hixson JE. Apolipoprotein E polymorphisms affect atherosclerosis in young males. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb 1991;11:1237-44.
39. Kamboh MI, Aston CE, Ferrell RE, Hamman RF. Impact of apolipoprotein E polymorphism in determining interindividual variation in total cholesterol and low density lipoprotein cholesterol in Hispanics and non-Hispanic whites. Atherosclerosis 1993;98:201-11.
40. Knouff C, Hinsdale ME, Mezdour H et al. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest 1999;103:1579-86.
41. Lahoz C, Schaefer EJ, Cupples LA et al. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 2001;154:529-37.
42. Ou T, Yamakawa-Kobayashi K, Arinami T et al. Methylenetetrahydrofolate reductase and apolipoprotein E polymorphisms are independent risk factors for coronary heart disease in Japanese: a case-control study. Atherosclerosis 1998;137:23-28.
43. Reilly SL, Ferrell RE, Kottke BA, Kamboh MI, Sing CF. The gender-specific apolipoprotein E genotype influence on the distribution of lipids and apolipoproteins in the population of Rochester, MN. I. Pleiotropic effects on means and variances. Am J Hum Genet 1991; 49:1155-66.
44. Reilly SL, Ferrell RE, Kottke BA, Sing CF. The gender-specific apolipoprotein E genotype influence on the distribution of plasma lipids and apolipoproteins in the population of Rochester, Minnesota. II. Regression relationships with concomitants. Am J Hum Genet 1992;51:1311-24.
45. Reilly SL, Ferrell RE, Sing CF. The gender-specific apolipoprotein E genotype influence on the distribution of plasma lipids and apolipoproteins in the population of Rochester, MN. III. Correlations and covariances. Am J Hum Genet 1994;55:1001-18.
46. Schaefer EJ, Lamon-Fava S, Johnson S et al. Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels. Results from the Framingham Offspring Study. Arterioscler Thromb 1994;14:1105-13.
47. Ukkola O, Kervinen K, Salmela PI, von Dickhoff K, Laakso M, Kesaniemi YA. Apolipoprotein E phenotype is related to macro- and microangiopathy in patients with non-insulin-dependent diabetes mellitus. Atherosclerosis 1993;101:9-15.
48. Wilson PW, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol 1996;16:1250-55.
49. Xhignesse M, Lussier-Cacan S, Sing CF, Kessling AM, Davignon J. Influences of common variants of apolipoprotein E on measures of lipid metabolism in a sample selected for health. Arterioscler Thromb 1991;11:1100-10.
50. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Jensen G, Tybjaerg-Hansen A. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation 2000; 101 1907-12.
51. Zhong S, Sharp DS, Grove JS et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996;97:2917-23.
52. Keavney B, Parish S, Palmer A et al. Large-scale evidence that the cardiotoxicity of smoking is not significantly modified by the apolipoprotein E E2/ E3/ E4 genotype. Lancet 2003; 361 396-98.
53. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxidty by oxidative insults and beta-amyloid peptides. Nat Genet 1996;14:55-61.
54. Davignon J. Apolipoprotein E polymorphism and atherosclerosis. In: Schwartz CJ, Born GVR (eds). New Horizons in Coronary Heart Disease. London: Current Science, 1993, 5.1-5.21.
55. Cullen P, Cignarella A, Brennhausen B, Mohr S, Assmann G, von Eckardstein A. Phenotype-dependent differences in apolipoprotein E metabolism and in cholesterol homeostasis in human monocyte-derived macrophages. J Clin Invest 1998; 101:1670-77.
56. Riddell DR, Graham A, Owen JS. Apolipoprotein E inhibits platelet aggregation through the L-arginine: nitric oxide pathway - Implications for vascular disease. J Biol Chem 1997;272 89-95.
57. Kelly ME, Clay MA, J. MM, Hsieh-Li HM, Harmony JAK. Apolipoprotein E inhibition of proliferation of mitogen -activated T-lymphocytes: production of interleukin-2 with reduced biological activity. Cell Immunol 1994;159:124-39.
58. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003;32:1-22.
59. Youngman L, Keavney B, Palmer A et al. Plasma fibrinogen and fibrinogen genotypes in 4685 cases of myocardial infarction and 6002 controls: test of causality by 'Mendelian randomisation'. Circulation 2000;102(Suppl.II):31-32.
60. Collins FS. Shattuck lecture-medical and societal consequences of the Human Genome Project. N Engl J Med. 1999; 341:28-37.